Phuong N. Huynh

Array ( [id] => 9222469 [patent_doc_number] => 20140017244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-16 [patent_title] => 'Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases' [patent_app_type] => utility [patent_app_number] => 13/940091 [patent_app_country] => US [patent_app_date] => 2013-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 24388 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13940091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10290708 [patent_doc_number] => 20150175707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'DIMERIC PROTEIN WITH TRIPLE MUTATIONS' [patent_app_type] => utility [patent_app_number] => 14/413178 [patent_app_country] => US [patent_app_date] => 2013-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 63 [patent_no_of_words] => 60945 [patent_no_of_claims] => 83 [patent_no_of_ind_claims] => 57 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14413178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9173933 [patent_doc_number] => 20130315918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'ANTI-VEGF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/929338 [patent_app_country] => US [patent_app_date] => 2013-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 54137 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13929338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9319498 [patent_doc_number] => 20140051836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-20 [patent_title] => 'Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use' [patent_app_type] => utility [patent_app_number] => 13/928182 [patent_app_country] => US [patent_app_date] => 2013-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 64609 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13928182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081051 [patent_doc_number] => 20130266581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'ANTI-VEGF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/926801 [patent_app_country] => US [patent_app_date] => 2013-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 53388 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13926801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12099227 [patent_doc_number] => 09856314 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'Activatable antibodies having non-binding steric moieties and methods of using the same' [patent_app_type] => utility [patent_app_number] => 13/924207 [patent_app_country] => US [patent_app_date] => 2013-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 25781 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13924207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9122329 [patent_doc_number] => 20130289251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-31 [patent_title] => 'BINDING AGENT' [patent_app_type] => utility [patent_app_number] => 13/923631 [patent_app_country] => US [patent_app_date] => 2013-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 24024 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13923631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10240477 [patent_doc_number] => 20150125473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-07 [patent_title] => 'NOVEL PROCESS FOR PREPARATION OF ANTIBODY CONJUGATES AND NOVEL ANTIBODY CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/407859 [patent_app_country] => US [patent_app_date] => 2013-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9623 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14407859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081044 [patent_doc_number] => 20130266571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'THREE-DIMENSIONAL STRUCTURE OF COMPLEMENT RECEPTOR TYPE 2 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/917278 [patent_app_country] => US [patent_app_date] => 2013-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 124165 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13917278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11859051 [patent_doc_number] => 09738724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-22 [patent_title] => 'Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use' [patent_app_type] => utility [patent_app_number] => 13/913345 [patent_app_country] => US [patent_app_date] => 2013-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 16 [patent_no_of_words] => 70947 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13913345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9212632 [patent_doc_number] => 20140011809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-09 [patent_title] => 'DRUG DELIVERY TO THE ANTERIOR AND POSTERIOR SEGMENTS OF THE EYE USING EYE DROPS' [patent_app_type] => utility [patent_app_number] => 13/912896 [patent_app_country] => US [patent_app_date] => 2013-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 13841 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13912896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11276090 [patent_doc_number] => 09492561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Dock-and-Lock (DNL) Complexes for delivery of interference RNA' [patent_app_type] => utility [patent_app_number] => 13/908914 [patent_app_country] => US [patent_app_date] => 2013-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 24241 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13908914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10882001 [patent_doc_number] => 08906378 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-09 [patent_title] => 'Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases' [patent_app_type] => utility [patent_app_number] => 13/904534 [patent_app_country] => US [patent_app_date] => 2013-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 43326 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13904534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414520 [patent_doc_number] => 10822396 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Repeat-chain for the production of dimer, multimer, multimer complex and super-complex [patent_app_type] => utility [patent_app_number] => 13/904824 [patent_app_country] => US [patent_app_date] => 2013-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 18496 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13904824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9181219 [patent_doc_number] => 20130323204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-05 [patent_title] => 'Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy' [patent_app_type] => utility [patent_app_number] => 13/901737 [patent_app_country] => US [patent_app_date] => 2013-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 46991 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13901737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9197679 [patent_doc_number] => 20130336994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-19 [patent_title] => 'EXTRACELLULAR TARGETED DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 13/897911 [patent_app_country] => US [patent_app_date] => 2013-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 49782 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13897911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9160949 [patent_doc_number] => 20130309226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-21 [patent_title] => 'HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 13/896622 [patent_app_country] => US [patent_app_date] => 2013-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17369 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13896622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9016501 [patent_doc_number] => 20130231464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-05 [patent_title] => 'METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS' [patent_app_type] => utility [patent_app_number] => 13/892705 [patent_app_country] => US [patent_app_date] => 2013-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 12688 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13892705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10869816 [patent_doc_number] => 08895008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-25 [patent_title] => 'Compositions and methods relating to anti-IGF-1 receptor antibodies' [patent_app_type] => utility [patent_app_number] => 13/891781 [patent_app_country] => US [patent_app_date] => 2013-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 43 [patent_no_of_words] => 46742 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13891781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9004543 [patent_doc_number] => 20130225668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-29 [patent_title] => 'ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 13/875560 [patent_app_country] => US [patent_app_date] => 2013-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 26672 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13875560 [rel_patent_id] =>[rel_patent_doc_number] =>)